H9936; Administration of LMP Specific Cytotoxic T-lymphocytes to Patients with Relapsed EBV-Positive Hodgkin’s Disease (ALCI): This study uses allogeneic EBV specific T-lymphocytes to treat EBV positive lymphoma.
H8713; Phase I/II Study of Allogeneic Stem Cell Transplantation for Patients with Hematologic Malignancy, Using Haploidentical Family Donors and Sub-Myeloablative Conditioning with Campath 1H (HIMSUM): This study uses a monoclonal antibody, low dose chemotherapy and radiation combined with haploidentical allogeneic stem cell transplantation to treat patients with hematologic malignancies who have already received a stem cell transplant or who also have other complications such as kidney, liver, or heart disease.
H17946: Administration of TGF-β Resistant LMP-Specific Cytotoxic T-Lymphocytes to Patients with Relapsed EBV-Positive Lymphoma (TGFbeta): This study uses EBV specific T-Lymphocytes with a gene inserted to render them resistant to TGF-β to treat EBV positive lymphoma.
H26617; Phase I Study of the Administration of EBV CTLs Expressing CD30 Chimeric Receptors for Relapsed CD30+ Hodgkin’s Lymphoma and CD30+ Non-Hodgkin’s Lymphoma (CARCD30): This study uses a Chimeric Antigen Receptor (CAR) made from a monoclonal antibody that recognizes the CD30 molecule that is on Hodgkin lymphoma cells, and that is then expressed in a T lymphocyte that kills EBV infected cells. This combination targets Hodgkin lymphoma and some NHL that is CD30+ or EBV+ .
H27471; Administration of Tumor-Associated Antigen (TAA)-Specific Cytotoxic T-Lymphocytes to Patients with Active or Relapsed Hodgkin or Non-Hodgkin Lymphoma (TACTAL): This study uses T cells that have been trained to look for five (5) different proteins (called tumor associated antigens) that are frequently found on lymphoma cells. We hope these TAAs will help the CTLs find and kill lymphoma cells.
GH27721; Phase I Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor for Relapsed CD30+ Hodgkin’s Lymphoma and CD30+ non-Hodgkin’s Lymphoma (CARTCD30): This study uses a Chimeric Antigen Receptor (CAR) made from a monoclonal antibody that recognizes the CD30 molecule that is on Hodgkin lymphoma cells, and that is then expressed in a T lymphocyte which can target Hodgkin lymphoma that is CD30+.
H28361; Most Closely HLA-Matched Allogeneic LMP1/2-Specific Cytotoxic T Lymphocytes for Treatment of Patients with Relapsed EBV-Associated Diseases (MALTED): This study uses EBV specific T-lymphocytes generated from a donor to treat patients with EBV related disease.
H29617; Administration of Rapidly Generated LMP, BARF1 and EBNA1 Specific Cytotoxic T-Lymphocytes to Patients with EBV-positive Lymphoma (GRALE): This study uses autologous EBV specific T-Lymphocytes to treat lymphoma. Compared to some of our other similar studies, the cells used in this study are generated in the laboratory using a faster and simpler technique.